Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Loop Capital Analyst Downgrades Big Lots to Sell Rating with Revised Price Target

Elaine Mendonca by Elaine Mendonca
February 12, 2024
in Breaking News
0
Retail Stock Bull Market
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

On February 12, 2024, Loop Capital analyst Anthony Chukumba made a significant move by downgrading Big Lots (NYSE: BIG) from a Hold to a Sell rating, while also revising the price target from $6 to $1. This decision reflects a pessimistic perspective on the company’s stock. While the specific reasons behind the downgrade remain undisclosed, it is likely influenced by a combination of factors including the company’s performance, prevailing industry trends, and overall market conditions. As a result, investors and stakeholders closely monitoring Big Lots may find this information valuable when contemplating their investment decisions.

Analysis of BIG Stock Performance on February 12, 2024: Concerning Trends and Potential Downward Trend

On February 12, 2024, the stock performance of BIG showed some concerning trends. The stock was trading near the bottom of its 52-week range and below its 200-day simple moving average, indicating a potential downward trend.

The stock had dropped by $0.21, representing a 3.77% decrease, bringing the closing price down to $5.36.

In pre-market trading, the stock experienced an additional drop of $1.01, suggesting that the downward trend might continue throughout the day.

The combination of trading near the bottom of its 52-week range, being below its 200-day simple moving average, and experiencing a significant drop in both after-hours and pre-market trading indicated that BIG’s stock performance on February 12, 2024, was not favorable.

Investors and analysts would likely be closely monitoring the stock’s performance throughout the day to assess whether this downward trend persists or if there are any signs of a potential recovery. It is important to note that stock market performance can be influenced by various factors, including company-specific news, industry trends, and overall market sentiment. Therefore, it would be prudent to consider these factors and conduct further research before making any investment decisions related to BIG stock.

Analyzing BIG Stock Performance on February 12, 2024: Total Revenue Decline, Net Income Fluctuations, and EPS Analysis

Title: BIG Stock Performance on February 12, 2024: A Closer Look at the Numbers

Introduction:
On February 12, 2024, the stock performance of BIG caught the attention of investors and analysts. This article delves into the financial figures of BIG, focusing on its total revenue, net income, and earnings per share (EPS). By examining the changes in these metrics since last year and last quarter, we can gain insights into the company’s recent performance.

Total Revenue Decline:
Over the past year, BIG’s total revenue stood at $5.47 billion, marking a decline of 11.09% compared to the previous year. Furthermore, the company experienced a 9.89% decrease in total revenue since the last quarter, with figures amounting to $1.03 billion. This decline in revenue signals a challenging period for BIG.

Net Income Fluctuations:
BIG’s net income figures reveal a mixed performance. In the span of one year, the company reported a net loss of -$210.71 million, representing a substantial decrease of 218.52% compared to the previous year. However, the net income for the last quarter showed a positive turnaround, with a modest increase of 101.9% to $4.74 million. This increase in net income from the previous quarter indicates that BIG may have implemented strategic measures to improve its profitability.

Earnings per Share (EPS) Analysis:
The company’s earnings per share (EPS) figures provide additional insights into BIG’s financial performance. Over the course of one year, the EPS dropped significantly by 236.98% to -$7.30. However, in the last quarter, there was a remarkable increase of 101.89% to $0.16. This improvement in EPS suggests that BIG has taken steps to enhance its profitability and generate more value for its shareholders.

Conclusion:
BIG’s stock performance on February 12, 2024, reflected a decline in total revenue over the past year and the last quarter. The company faced challenges, resulting in an 11.09% decrease in total revenue since last year and a 9.89% decrease since the previous quarter. However, the net income and EPS figures present a more nuanced picture. While BIG experienced a significant net loss of -$210.71 million over the year, it managed to turn the tide with a 101.9% increase in net income in the last quarter. Similarly, the EPS showed a substantial improvement of 101.89% in the same period. These positive changes suggest that BIG has implemented effective strategies to enhance its profitability and generate value for its shareholders. Investors and analysts will closely monitor the company’s future financial performance to assess its ability to sustain this positive momentum.

Tags: BIG
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biopharmaceutical Markets and money (1)

Immunovant Reports Impressive Quarterly Performance and Strong Financial Position

Biotechnology Market Capitalization

Calidi Biotherapeutics Unveils Revolutionary Systemic Enveloped Oncolytic Virotherapy Platform

Tonix Pharmaceuticals Receives FDA Clearance for Phase 2 OASIS Trial of TNX102 SL for Acute Stress Disorders

Recommended

SKYX Platforms Stock

Marriott Partnership Signals Major Breakthrough for SKYX Platforms

5 months ago
Microsoft Stock

Microsoft’s AI Ambition: A High-Stakes Bet on Future Growth

18 hours ago
Turtle Beach Stock

Turtle Beach Forges PlayStation Alliance with New Gaming Headset

5 months ago
FLO stock news

Cemtrex Shares Surge After Halting Trading Due to Circuit Breaker

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Fossil Group Stock Surges Past Key Technical Threshold

NextGen Healthcare: Strategic Wins and Industry Accolades Signal Sustained Momentum

Trending

Rolls Royce Stock
Defense & Aerospace

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

by Dieter Jaworski
February 5, 2026
0

The coming weeks represent a critical juncture for Rolls-Royce. The company is poised to demonstrate whether it...

Viking Therapeutics Stock

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

February 5, 2026
Solana Stock

Solana Faces Billions in Potential Token Supply Releases

February 5, 2026
CureVac Stock

CureVac Delisted Following BioNTech Acquisition Completion

February 5, 2026
EOS Stock

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rolls-Royce Shares: A Pivotal Period for Growth and Diversification
  • Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report
  • Solana Faces Billions in Potential Token Supply Releases

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com